Close Menu

All Good Things...

Despite its well-received genome-wide association scan papers, DeCode Genetics is on the brink of extinction, says Technology Review. According to the article, DeCode has spent more than $600 million, never made a profit, and has $3.7 million left as its stock hovers at 57 cents, down from $29 when the company first launched. Founder Kari Stefansson recently told investors that he is re-envisioning DeCode as a gene-based diagnostics company.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.